Venetoclax: all 546 studies that test it
Page 2 of 6. Open to participants first (240), then studies with results posted, then the rest; newest registration first within each.
- De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding PatientsRecruitingNCT06557421Phase 2
- Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALLRecruitingNCT06554626Phase 2
- A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)RecruitingNCT06548230Phase 1/2
- Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia PatientsEnrolling by invitationNCT06544109Phase 2/3
- Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid LeukemiaRecruitingNCT06537843Phase 2
- VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDSRecruitingNCT06536959Phase 2
- Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AMLRecruitingNCT06536010Not applicable
- A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingNCT06520098Phase 2
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLNot yet recruitingNCT06516978Phase 2
- Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRDRecruitingNCT06511882Phase 2
- Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaRecruitingNCT06510309Phase 2
- Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AMLRecruitingNCT06504459Phase 2
- Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.RecruitingNCT06483906Phase 2
- Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALLRecruitingNCT06481241Not applicable
- Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALLRecruitingNCT06481228Not applicable
- Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular LymphomaRecruitingNCT06471738Phase 2
- A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated LeukemiasRecruitingNCT06466395Phase 1
- Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKiRecruitingNCT06466122Phase 2
- Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AMLRecruitingNCT06451861Phase 2
- A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaRecruitingNCT06448013Phase 1
- Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor OlutasidenibRecruitingNCT06445959Phase 1/2
- Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AMLRecruitingNCT06434662Phase 2
- Mitoxantrone for Venetoclax Resistant Acute Myeloid LeukemiaRecruitingNCT06429449Phase 1
- Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaRecruitingNCT06399640Phase 1
- A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute LeukemiasRecruitingNCT06397027Phase 1
- Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALLRecruitingNCT06393985Phase 2
- Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)RecruitingNCT06390319Phase 2
- DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT06382168Phase 1/2
- A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDSRecruitingNCT06372717Phase 1
- Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALLRecruitingNCT06361329Phase 3
- Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT06357182Phase 1
- Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.RecruitingNCT06328179Not applicable
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingNCT06317662Phase 2
- A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and RevumenibRecruitingNCT06284486Phase 1/2
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNCT06265545Not applicable
- Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AMLRecruitingNCT06232694Not applicable
- Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AMLRecruitingNCT06221683Phase 2
- Optimize First-line Treatment for AL Amyloidosis With t (11; 14)RecruitingNCT06192979Not applicable
- A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)RecruitingNCT06191978Phase 1
- Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AMLRecruitingNCT06191263Phase 2
- Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaRecruitingNCT06177067Phase 1
- Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AMLRecruitingNCT06156579Phase 2
- CIML NK Cells With Venetoclax for AMLRecruitingNCT06152809Phase 1
- Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell TransplantRecruitingNCT06129734Phase 1/2
- A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple MyelomaRecruitingNCT06115135Phase 2
- A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma PatientsNot yet recruitingNCT06087419Phase 1/2
- Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT06084819Phase 2
- Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic LeukemiaRecruitingNCT06082934Phase 1/2
- CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).RecruitingNCT06078306Phase 2
- Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDSRecruitingNCT06046313Phase 2
- A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AMLRecruitingNCT06014489Phase 2
- Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AMLRecruitingNCT05986240Phase 1
- VA vs DA for Newly Diagnosed Hig-risk AMLRecruitingNCT05939180Phase 2/3
- Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT05910801Phase 2
- Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete RemissionRecruitingNCT05909293Not applicable
- Venetoclax Combined With Azactidine in the Treatment of ALALRecruitingNCT05901974Phase 2
- Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic LeukemiaRecruitingNCT05881265Phase 2
- Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCLNot yet recruitingNCT05863845Not applicable
- Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple MyelomaRecruitingNCT05853965Phase 1/2
- Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.RecruitingNCT05841771Phase 2
- A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)RecruitingNCT05834244Phase 1
- Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAMLRecruitingNCT05807932Phase 1/2
- Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid LeukemiaRecruitingNCT05807347Phase 2
- Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AMLRecruitingNCT05805098Phase 2/3
- Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLLRecruitingNCT05791409Phase 1/2
- HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05751044Phase 1/2
- HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05745714Phase 1/2
- Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD ResultsRecruitingNCT05736978Phase 2
- A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid LeukemiaRecruitingNCT05736965Phase 2
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLRecruitingNCT05735184Phase 1
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
- Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ARTRecruitingNCT05668026Phase 1/2
- Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic LeukemiaRecruitingNCT05660473Phase 2
- CAV Regimen for R/R Ph- B-ALLRecruitingNCT05657652Not applicable
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial TreatmentNot yet recruitingNCT05628623Phase 2
- Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05597306Phase 1
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingNCT05564390Phase 2
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)Not yet recruitingNCT05554419Phase 2
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingNCT05554406Phase 2
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)RecruitingNCT05554393Phase 2
- Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLHRecruitingNCT05546060Phase 1
- Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)RecruitingNCT05536349Phase 2
- Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple MyelomaRecruitingNCT05530421Phase 2
- Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) PatientsRecruitingNCT05529069Phase 2
- Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid LeukemiaRecruitingNCT05522192Phase 1/2
- Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05506332Phase 1
- A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AMLRecruitingNCT05503355Phase 1/2
- Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating AgentsRecruitingNCT05442216Phase 2
- Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML ProfilingRecruitingNCT05431257Phase 2
- AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First RemissionRecruitingNCT05404906Phase 2/3
- IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)RecruitingNCT05401097Phase 2
- Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL PatientsRecruitingNCT05376111Phase 2
- A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess BlastsRecruitingNCT05365035Phase 2
- A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)RecruitingNCT05360160Phase 1/2
- Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDSRecruitingNCT05342584Phase 1
- Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic LeukemiaRecruitingNCT05336812Phase 2
- Venetoclax to Augment Epigenetic Modification and ChemotherapyRecruitingNCT05317403Phase 1
- CC-486 and Venetoclax for Acute Myeloid LeukemiaRecruitingNCT05287568Phase 1
- Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAMLRecruitingNCT05262465Not applicable
- Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AMLRecruitingNCT05184842Phase 2Results posted